Skye Bioscience, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-55.9M | $-26.6M | $-37.6M | $-19.5M | $-8.5M | $-6.6M | $1.1M | $-19.2M |
| Depreciation & Amortization | $723.4K | $298.6K | $124.3K | — | — | — | — | — |
| Depreciation | $540.1K | $203.8K | $49.9K | $115.0K | $34.1K | $1.9K | $1.5K | $1.5K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $7.8M | $8.3M | $987.5K | $629.0K | $869.2K | $302.7K | $680.5K | $675.0K |
| Net Cash from Operating Activities | $-43.1M | $-25.2M | $-14.0M | $-12.7M | $-6.5M | $-6.1M | $-6.0M | $-3.9M |
| Investing Activities | ||||||||
| Capital Expenditures | $6.3K | $1.6M | $12.6K | $28.1K | $90.9K | $7.2K | — | $4.4K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-19.5M | $-245.6K | $6.6M | $5.2M | $-90.9K | $-7.2K | — | $-4.4K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $29.6K | $83.6M | $16.4M | $-208.8K | $13.1M | $6.7M | $6.0M | $5.5M |
| Net Change in Cash | $-62.5M | $58.1M | $9.1M | $-7.7M | $6.5M | $639.5K | $-23.4K | $1.6M |
| Free Cash Flow | $-43.1M | $-26.8M | $-14.0M | $-12.8M | $-6.6M | $-6.1M | — | $-3.9M |